Data Insights

Triheptanoin by Ultragenyx Pharmaceutical for Neurodegenerative Diseases: Likelihood of Approval

Triheptanoin is under clinical development by Ultragenyx Pharmaceutical and currently in Phase I for Neurodegenerative Diseases. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Triheptanoin in Neurodegenerative Diseases

Data Insights

GTX-102 by Ultragenyx Pharmaceutical for Angelman Syndrome: Likelihood of Approval

GTX-102 is under clinical development by Ultragenyx Pharmaceutical and currently in Phase III for Angelman Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - GTX-102 in Angelman Syndrome

Data Insights

Pariglasgene brecaparvovec by Ultragenyx Pharmaceutical for Glycogen Storage Disease 1A: Likelihood of Approval

Pariglasgene brecaparvovec is under clinical development by Ultragenyx Pharmaceutical and currently in Phase III for Glycogen Storage Disease 1A. According...

Data Insights

Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's Rivunatpagene Miziparvovec?

Rivunatpagene Miziparvovec is a gene therapy commercialized by Ultragenyx Pharmaceutical, with a leading Phase III program in Wilson Disease. According...

Net Present Value Model: Ultragenyx Pharmaceutical Inc's Rivunatpagene Miziparvovec

Data Insights

Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's Avalotcagene Ontaparvovec?

Avalotcagene Ontaparvovec is a gene therapy commercialized by Ultragenyx Pharmaceutical, with a leading Phase III program in Ornithine-Transcarbamylase Deficiency. According...

Net Present Value Model: Ultragenyx Pharmaceutical Inc's Avalotcagene Ontaparvovec

Data Insights

Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's Pariglasgene Brecaparvovec?

Pariglasgene Brecaparvovec is a gene therapy commercialized by Ultragenyx Pharmaceutical, with a leading Phase III program in Glycogen Storage Disease...

Net Present Value Model: Ultragenyx Pharmaceutical Inc's Pariglasgene Brecaparvovec

Data Insights

Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's Rebisufligene Etisparvovec?

Rebisufligene Etisparvovec is a gene therapy commercialized by Ultragenyx Pharmaceutical, with a leading Phase III program in Mucopolysaccharidosis III (MPS...

Net Present Value Model: Ultragenyx Pharmaceutical Inc's Rebisufligene Etisparvovec

Data Insights

Setrusumab by Ultragenyx Pharmaceutical for Osteogenesis Imperfecta: Likelihood of Approval

Setrusumab is under clinical development by Ultragenyx Pharmaceutical and currently in Phase III for Osteogenesis Imperfecta. According to GlobalData, Phase...